CVI Holdings’s Aspire Biopharma ASBP Stock Holding History

CVI Holdings’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-42	Closed	-$507K	–	657
2022 Q3	$507K	Hold	42	–	–	0.04%	394
2022 Q2	$499K	Buy	+42	New	+$503K	0.04%	422

Other funds holding ASBP

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

CVI Holdings's ASBP Position: Q4 2022 in Review

CVI Holdings sold out of Aspire Biopharma (ASBP) in Q4 2022, closing a stake of 42 shares — an estimated $507K sold.

CVI Holdings first reported a position in ASBP in Q2 2022 and held it in 2 quarters. The position peaked at $507K in Q3 2022. 55 funds tracked by Wall St. Rank hold ASBP as of Q4 2022.

CVI Holdings reported no remaining Aspire Biopharma position as of Q4 2022 after selling out during the quarter.
CVI Holdings sold 42 Aspire Biopharma shares in Q4 2022, an estimated $507K.
CVI Holdings first reported a position in Aspire Biopharma in Q2 2022 and held it in 2 quarters.
CVI Holdings's Aspire Biopharma position peaked at $507K in Q3 2022.
55 funds tracked by Wall St. Rank held Aspire Biopharma as of Q4 2022.

Based on CVI Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.